In a recent meta-analysis, IDH1/2 mutations showed no OS affect in the whole AML population; however, IDH1 mutation conferred a worse OS in patients with CN-AML (OS: HR, 1.21; 95% CI, 1.01–1.46) [30]. The gene discussed is IDH1; the disease is acute myeloid leukemia.